Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Mai EK, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, Fenk R, Schlenzka J, Munder M, Dürig J, Blau IW, Huhn S, Hose D, Jauch A, Kunz C, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A, Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens UM, Kunz C, Hensel M, Benner A, Seidel-Glätzer A, Weisel KC, Raab MS, Salwender HJ; German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators. Mai EK, et al. Among authors: schlenzka j. Lancet Haematol. 2024 Feb;11(2):e101-e113. doi: 10.1016/S2352-3026(23)00366-6. Lancet Haematol. 2024. PMID: 38302221 Free article. Clinical Trial.
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Baertsch MA, Mai EK, Hielscher T, Bertsch U, Salwender HJ, Munder M, Fuhrmann S, Dührsen U, Brossart P, Neben K, Schlenzka J, Kunz C, Raab MS, Hillengaß J, Jauch A, Seckinger A, Hose D, Luntz S, Sonneveld P, Lokhorst H, Martin H, Goerner M, Hoffmann M, Lindemann HW, Bernhard H, Blau IW, Scheid C, Besemer B, Weisel KC, Hänel M, Dürig J, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG). Baertsch MA, et al. Among authors: schlenzka j. Blood Cancer J. 2021 Jan 7;11(1):1. doi: 10.1038/s41408-020-00390-3. Blood Cancer J. 2021. PMID: 33414374 Free PMC article. Clinical Trial.
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengaß J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H. Baertsch MA, et al. Among authors: schlenzka j. BMC Cancer. 2016 Apr 25;16:290. doi: 10.1186/s12885-016-2321-2. BMC Cancer. 2016. PMID: 27114074 Free PMC article. Clinical Trial.
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
Baertsch MA, Schlenzka J, Lisenko K, Krzykalla J, Becker N, Weisel K, Noppeney R, Martin H, Lindemann HW, Haenel M, Nogai A, Scheid C, Salwender H, Fenk R, Graeven U, Reimer P, Schmidt-Hieber M, Goerner M, Schmidt-Wolf IGH, Klein S, Ho AD, Goldschmidt H, Wuchter P. Baertsch MA, et al. Among authors: schlenzka j. Eur J Haematol. 2017 Jul;99(1):42-50. doi: 10.1111/ejh.12888. Epub 2017 May 24. Eur J Haematol. 2017. PMID: 28370401 Clinical Trial.
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.
Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG). Mai EK, et al. Among authors: schlenzka j. Leukemia. 2019 Jan;33(1):258-261. doi: 10.1038/s41375-018-0195-9. Epub 2018 Jun 29. Leukemia. 2019. PMID: 29959413 Clinical Trial. No abstract available.
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, Raab MS, Hillengass J, Sauer S, Müller-Tidow C, Luntz S, Jauch A, Hose D, Seckinger A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann HW, Scheid C, Nogai A, Salwender H, Noppeney R, Besemer B, Weisel K; German Myeloma Multicenter Group (GMMG). Goldschmidt H, et al. Among authors: schlenzka j. Leukemia. 2021 Apr;35(4):1134-1144. doi: 10.1038/s41375-020-0948-0. Epub 2020 Jul 21. Leukemia. 2021. PMID: 32694619 Clinical Trial.
A systematic classification of death causes in multiple myeloma.
Mai EK, Haas EM, Lücke S, Löpprich M, Kunz C, Pritsch M, Knaup-Gregori P, Raab MS, Schlenzka J, Bertsch U, Hillengass J, Goldschmidt H. Mai EK, et al. Among authors: schlenzka j. Blood Cancer J. 2018 Mar 8;8(3):30. doi: 10.1038/s41408-018-0068-5. Blood Cancer J. 2018. PMID: 29520024 Free PMC article. Clinical Trial. No abstract available.
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H; Dutch-Belgian HOVON; German GMMG. Lokhorst HM, et al. Among authors: schlenzka j. Haematologica. 2008 Jan;93(1):124-7. doi: 10.3324/haematol.11644. Haematologica. 2008. PMID: 18166796 Free article. Clinical Trial.